Next Generation Drug Delivery Technologies Push Markets Past $41 Billion by 2007, Says Frost & Sullivan.Business Editors & Health/Medical Writers SAN JOSE, Calif.--(BUSINESS WIRE)--May 31, 2001 Oral drug ingestion ingestion /in·ges·tion/ (-chun) the taking of food, drugs, etc., into the body by mouth. in·ges·tion n. 1. The act of taking food and drink into the body by the mouth. 2. continues to be the predominant choice of U.S. physicians, but inhalation therapy inhalation therapy n. The therapeutic use of gases or of aerosols by inhalation. and sustained release injections are expected to hold the key to future growth of the U.S. drug delivery markets. According to new analysis by Frost & Sullivan's healthcare group (www.healthcare.frost.com), the U.S. Emerging Drug Delivery Technology Markets are expected to grow from $19 billion in 2001 to $41 billion by 2007. "The growth of the drug delivery industry will be driven by the application of novel delivery technologies to biotechnology drugs," says Frost & Sullivan Pharmaceutical Industry Analyst Dhiraj Ajmani. "Pulmonary drug delivery technologies for insulin and other proteins are expected to be commercialized in 2002-2004 and will have multi-billion dollar market potential." Some of the notable molecules expected to hit the market in the future include Inhalable insulin, NESP NESP Neuroendocrine Secretory Protein NESP Navy EHF SATCOM Program NESP Nurse Educator Scholarship Program NESP Navy EHF Satellite Program NESP National Environmental Studies Project NESP National Education Supercomputer Program , Buspar TDS TDS total dissolved solids. , Viagra Zydis, Insulin oral spray, Oral Heparin, Alprox-TD and Evra TDS. When incorporated into the earliest stages of drug development, drug delivery technologies become an integral part of the entire drug development process. This kind of integration produces drugs that focus on patient compliance and convenience, which will best serve the interests of the total drug delivery technology markets. "U.S. Emerging Drug Delivery Technology Markets" analyzes the following key product segments: Oral controlled/sustained release tablets or capsules, immediate release systems, transdermal creams and patches, CFC-free metered dose and dry powder inhalers, Buccal buc·cal adj. 1. Of, relating to, adjacent to, or in the direction of the cheek. 2. Of or relating to the mouth cavity. buccal tablets and patches, nasal preparations, sustained release/depot parenteral parenteral /pa·ren·ter·al/ (pah-ren´ter-al) not through the alimentary canal, but rather by injection through some other route, as subcutaneous, intramuscular, etc. par·en·ter·al adj. 1. formulations, needle-free injections and sustained release implants. The research does not analyze the markets for traditional inhalation therapies Inhalation Therapies Definition Inhalation therapies are a group of respiratory, or breathing, treatments designed to help restore or improve breathing function in patients with a variety of diseases, conditions, or injuries. , which use CFC CFC See: Controlled foreign corporation propellants. Frost & Sullivan presents the 2001 Marketing Engineering Awards to companies that have worked diligently to make a positive contribution to the drug delivery industry. These market specific awards are presented to Alkeremes, Alza Corporation, Elan Corporation, Emisphere Technologies, Inhale Therapeutics and Generex Biotechnology. Frost & Sullivan is a global leader in international strategic market consulting and training. This ongoing research is part of the frost.com Pharmaceuticals Monitor Service, which includes market analyses on U.S. Asthma Therapeutic Markets and European Epilepsy Drug Markets. Frost & Sullivan also offers custom consulting to a variety of national and international companies. Executive summaries and interviews are available to the press. U.S. Drug Delivery Technology Markets Report: 7858-52 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion